News stories about OncoSec Medical (NASDAQ:ONCS) have trended somewhat positive recently, Accern Sentiment reports. The research firm scores the sentiment of media coverage by analyzing more than twenty million news and blog sources. Accern ranks coverage of publicly-traded companies on a scale of negative one to positive one, with scores closest to one being the most favorable. OncoSec Medical earned a media sentiment score of 0.19 on Accern’s scale. Accern also assigned press coverage about the biotechnology company an impact score of 45.9050914814313 out of 100, meaning that recent media coverage is somewhat unlikely to have an effect on the company’s share price in the near term.

These are some of the news stories that may have impacted Accern Sentiment Analysis’s scoring:

Several brokerages have recently weighed in on ONCS. ValuEngine lowered shares of OncoSec Medical from a “sell” rating to a “strong sell” rating in a report on Monday, October 2nd. Maxim Group set a $5.00 price objective on shares of OncoSec Medical and gave the stock a “buy” rating in a report on Thursday, December 14th. Finally, HC Wainwright set a $6.00 price objective on shares of OncoSec Medical and gave the stock a “buy” rating in a report on Friday, December 15th. One equities research analyst has rated the stock with a sell rating and four have assigned a buy rating to the stock. The company presently has an average rating of “Buy” and an average price target of $5.33.

Shares of OncoSec Medical (NASDAQ:ONCS) remained flat at $$1.87 during mid-day trading on Thursday. The stock had a trading volume of 841,900 shares, compared to its average volume of 994,600. The firm has a market capitalization of $66.42, a PE ratio of -1.76 and a beta of 3.25. OncoSec Medical has a 52 week low of $0.88 and a 52 week high of $2.95.

OncoSec Medical (NASDAQ:ONCS) last announced its quarterly earnings data on Wednesday, October 25th. The biotechnology company reported ($0.28) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.23) by ($0.05). research analysts anticipate that OncoSec Medical will post -0.86 earnings per share for the current year.

TRADEMARK VIOLATION NOTICE: “Somewhat Positive Media Coverage Somewhat Unlikely to Affect OncoSec Medical (ONCS) Stock Price” was first reported by The Cerbat Gem and is the property of of The Cerbat Gem. If you are viewing this article on another domain, it was stolen and reposted in violation of U.S. and international trademark and copyright laws. The correct version of this article can be viewed at

About OncoSec Medical

OncoSec Medical Incorporated is a biotechnology company. The Company is focused on designing, developing and commercializing gene therapies, therapeutics and medical approaches to stimulate an anti-tumor immune response for the treatment of cancer. The Company’s lead product candidate, ImmunoPulse IL-12, consists of a plasmid construct encoding the proinflammatory cytokine, IL-12, which is delivered into the tumor through in vivo electroporation.

Insider Buying and Selling by Quarter for OncoSec Medical (NASDAQ:ONCS)

Receive News & Stock Ratings for OncoSec Medical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for OncoSec Medical and related stocks with our FREE daily email newsletter.